Type II topoisomerases like DNA gyrase initiate ATP-dependent negative supercoils in bacterial DNA. It is critical in all of the bacteria but is missing from eukaryotes, making it a striking target for antibacterials. Ciprofloxacin is a clinically approved drug, but its clinical effectiveness is affected by the emergence of resistance in both Gram-positive and Gram-negative bacteria. Thus, it is vital to identify novel compounds that can efficiently inhibit DNA gyrase, and quantitative structure-activity relationship (QSAR) modeling is a quick and economical means to do so. A QSAR-based virtual screening approach was applied to identify new gyrase inhibitors using an in-house-generated combinatorial library of 29828 compounds from seven ciprofloxacin scaffold structures. QSAR was built using a data set of 271 compounds, which were identified as positive and negative inhibitors from existing data reported in in vitro studies. The best QSAR model was developed using the 5-fold cross-validation Neural Network in Orange, and it was based on five PaDEL descriptors with an accuracy and sensitivity of 83%. As a result of screening of an in-house-built combinatorial library with the best-developed QSAR model, 675 compounds were identified as potential inhibitors of DNA gyrase. These inhibitors were further docked with DNA gyrase using AutoDock to compare the binding mode and score of the selected/screened compounds, and 615 compounds exhibited a docking score comparable to or lower than that of ciprofloxacin. Out of these, the top five analogues 902b, 9699f, 4419f, 5538f, and 898b reported in our study have binding scores of -13.81, -12.95, -12.52, -12.43, and -12.41 kcal/mol, respectively. The MD simulations of these five analogues for 100 ns supported the interaction stability of analogues with Escherichia coli DNA gyrase. Ninety-one per cent of the analogues screened by the QSAR model displayed better binding energy than ciprofloxacin, demonstrating the efficacy of the generated model. The NN-QSAR model proposed in this manuscript can be downloaded from https://github.com/ritu225/NN-QSAR_model.git.
1 December 2020 in Expert Review of Molecular Diagnostics
: Tuberculous meningitis (TBM) is the most devastating form of central nervous system tuberculosis (TB) and causes high mortality worldwide. Non-specific clinical manifestations and limited sensiti...
1 July 2021 in Current Pharmaceutical Biotechnology
Background: The major concern of today's time is the developing resistance in the most of the clinically derived pathogenic micro-organisms for the available drugs through several mechanisms. So, there is an acute need to develop novel molecules with drug like properties that can be effective against the otherwise resistant micro-organisms. Methods: New drugs can be developed using several methods like structure based drug design, ligand based drug design or by developing analogues of the available drugs to improve their effect further. But the smartness is to opt for the techniques that involve lower expenditure, lower failure rates and faster discovery rates. Results: Analogue based drug design (ABDD) is one such technique that researchers worldwide are opting to develop new drug like molecules with comparatively lower market values.They start by first designing the analogues sharing structural and pharmacological similarities to the existing drugs. This method embark on scaffold structures of available drugs already approved by the clinical trials, but are left ineffective because of resistance developed by the pathogens. Conclusion: In this review we have stated some recent examples of anti-fungal and anti-bacterial (antimicrobial) drugs that were designed based on ABDD technique. Also we have tried to focus on the in silico tools and techniques that can contribute for the designing and computational screening of the analogues, so that these can be further taken for in vitro screening to validate their better biological activities against the pathogens with comparatively reduced rates of failure.
: Fungal infections are considered a great threat to human life and are associated with high mortality and morbidity, especially in immunocompromised individuals. Fungal pathogens employ various defense mechanisms to evade the host immune system, which causes severe infections. The available repertoire of drugs for the treatment of fungal infections includes azoles, allylamines, polyenes, echinocandins, and antimetabolites. However, the development of multidrug and pandrug resistance to available antimycotic drugs increases the need to develop better treatment approaches. In this new era of -omics, bioinformatics has expanded options for treating fungal infections. This review emphasizes how bioinformatics complements the emerging strategies, including advancements in drug delivery systems, combination therapies, drug repurposing, epitope- based vaccine design, RNA-based therapeutics, and the role of gut-microbiome interactions to combat anti-fungal resistance. In particular, we focused on computational methods that can be useful to obtain potent hits, and that too in a short period.
6 December 2022 in Journal of Biomolecular Structure and Dynamics
There is great concern in the medical community due to rapid increase in antibiotic resistance, causing 700,000 deaths annually worldwide. Therefore, there is paramount need to develop novel and innovative antibacterial agents active against resistant bacterial strains. DNA gyrase is a crucial enzyme in bacterial replication that is absent in eukaryotes, making it effective curative target for antibacterials. To identify potential DNA gyrase inhibitors by virtual screening of NCI database using a 3-step approach. A total of 271 compounds with known IC50 values against Escherichia coli DNA GyrA were selected to develop a pharmacophore model for dual screening approach to identify new potential hits from the NCI database. In the second step, the NCI database was also screened using in-house built NN-QSAR model. Molecular docking of common 5298 compounds screened from both methods were performed against E. coli DNA GyrA (PDB id- 6RKU), and 3004 compounds are reported to exhibit lower binding energies than ciprofloxacin (-6.77 Kcal/mol). The top three compounds (NCI371878, NCI371876 and NCI142159) reported with binding energy of -13.5, -13.19 and -13.03 Kcal/mol were further subjected to MD simulation studies for 100 ns supporting the stability of the docked complexes.
In-silico epitope-based vaccine is the cornerstone of modern vaccine development and is illuminating by a growing number of experimental and computational methods. The reverse vaccinology approach uses computational screening of the whole proteome of a pathogen to identify the proteins with the attributes of potential vaccine targets. The selection of the right components [antigenic determinants, linkers, and intramolecular adjuvants] results in the development of a multi-epitope vaccine construct with maximum efficacy and minimum adverse effects. We provide insight into the recent advancement in epitope-based vaccines and the procedure to design the modern or next-generation vaccine. The synergy between the computational screening of vaccine candidates and experimental verification to assess the immunogenic potential improves decision-making and reduces the cost and time of the development of new therapeutics